BioSpace News Archive

Genetown

ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress

ImmunoGen Inc, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine

October 20, 2018
·
6 min read
Drug Development

Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA,

October 20, 2018
·
27 min read
Biotech Bay

Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC).

October 20, 2018
·
16 min read
Drug Development

TWi Biotechnology, Inc. Announced the initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa

TWi Biotechnology, Inc. today announced that it has enrolled the first patient in a phase 2 trial of AC-203 for the treatment of inherited Epidermolysis Bullosa (EB).

October 20, 2018
·
4 min read
Policy

CVSI ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CV Sciences, Inc.; Important Oct. 23 Deadline - CVSI

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CV Sciences, Inc. (OTC: CVSI) from June 19, 2017 through August 20, 2018

October 20, 2018
·
2 min read
Pharm Country

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine

October 20, 2018
·
12 min read
Biotech Bay

Varian Introduces New ProBeam 360° Proton Therapy System

Varian (NYSE: VAR) today announced its new single-room proton therapy system, ProBeam® 360°.

October 20, 2018
·
2 min read